Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Grundy (San Diego, United States of America), A. Blackburn (San Diego, United States of America), E. Parsley (San Diego, United States of America), Y. Tang (San Diego, United States of America), C. King (San Diego, United States of America), J. Adams (San Diego, United States of America). Clinical pharmacokinetic (PK) performance of a ralinepag extended-release (XR) tablet. 3037

Member's Comments

No comment yet.

Related content which might interest you:

• The impact of anti-IgE treatment on the airway microbiome in asthma.
• Quality Improvement in a Sleep Clinic: To increase the capacity and reduce the time to treatment for patients with Obstructive Sleep Apnoea
• Endoscopic lung volume reduction with endobronchial valves in very low DLCO patients